IL303374A - Aptamers that bind to T lymphocytes - Google Patents
Aptamers that bind to T lymphocytesInfo
- Publication number
- IL303374A IL303374A IL303374A IL30337423A IL303374A IL 303374 A IL303374 A IL 303374A IL 303374 A IL303374 A IL 303374A IL 30337423 A IL30337423 A IL 30337423A IL 303374 A IL303374 A IL 303374A
- Authority
- IL
- Israel
- Prior art keywords
- aptamer
- cell
- cancer
- carcinoma
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121080P | 2020-12-03 | 2020-12-03 | |
| US202163257402P | 2021-10-19 | 2021-10-19 | |
| PCT/IB2021/000849 WO2022118077A2 (en) | 2020-12-03 | 2021-12-03 | T-lymphocyte binding aptamers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL303374A true IL303374A (en) | 2023-08-01 |
Family
ID=80446452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL303374A IL303374A (en) | 2020-12-03 | 2021-12-03 | Aptamers that bind to T lymphocytes |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12146140B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4256057A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7837345B2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL303374A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022118077A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12146140B2 (en) | 2020-12-03 | 2024-11-19 | Aummune Ltd. | T-lymphocyte binding aptamers |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2690441A1 (en) * | 2012-07-26 | 2014-01-29 | Rheinische Friedrich-Wilhelms-Universität Bonn | Method of determining a protein in a sample |
| US11219635B2 (en) * | 2016-02-19 | 2022-01-11 | City Of Hope | Bi-specific aptamer |
| CN107129988A (zh) | 2016-02-29 | 2017-09-05 | 广西医科大学 | 一种特异性结合cd3的核酸适配体及其筛选方法和应用 |
| WO2018017827A1 (en) | 2016-07-22 | 2018-01-25 | Fred Hutchinson Cancer Research Center | Bi-specific molecule for cell-specific notch inhibition and related methods and compositions |
| WO2019035763A1 (en) | 2017-08-16 | 2019-02-21 | Agency For Science, Technology And Research | APTAMERS FOR DETECTION OF ZIKA FLAVIVIRAL PROTEIN |
| US10584340B2 (en) * | 2017-09-29 | 2020-03-10 | University Of Florida Research Foundation, Inc. | Tau protein-binding DNA aptamers with capture/detection and therapeutic utilities in tauopathy-related neurodegenerative disorders |
| CN113423833B (zh) | 2018-09-28 | 2024-09-17 | 奥曼尼提纳米有限公司 | 用于选择功能性适体的方法和组合物 |
| US20230193286A1 (en) | 2020-05-20 | 2023-06-22 | Aummune Ltd. | Cytotoxic t-lymphocyte binding aptamers |
| US20230193285A1 (en) | 2020-05-20 | 2023-06-22 | Aummune Ltd. | Bispecific personalized aptamers |
| US12146140B2 (en) | 2020-12-03 | 2024-11-19 | Aummune Ltd. | T-lymphocyte binding aptamers |
-
2021
- 2021-12-03 US US17/542,046 patent/US12146140B2/en active Active
- 2021-12-03 EP EP21854938.4A patent/EP4256057A2/en active Pending
- 2021-12-03 IL IL303374A patent/IL303374A/en unknown
- 2021-12-03 JP JP2023557840A patent/JP7837345B2/ja active Active
- 2021-12-03 WO PCT/IB2021/000849 patent/WO2022118077A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP7837345B2 (ja) | 2026-03-30 |
| WO2022118077A2 (en) | 2022-06-09 |
| EP4256057A2 (en) | 2023-10-11 |
| US20220186223A1 (en) | 2022-06-16 |
| US12146140B2 (en) | 2024-11-19 |
| WO2022118077A3 (en) | 2022-09-29 |
| JP2023553193A (ja) | 2023-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10858658B2 (en) | Compositions and methods for inhibiting gene expression of factor XII | |
| KR102021626B1 (ko) | Ngf에 대한 압타머 및 그의 용도 | |
| US20180243436A1 (en) | Therapeutic cell internalizing conjugates | |
| UA130735C2 (uk) | РНКі-АГЕНТ І КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ АПОЛІПОПРОТЕЇНУ C-III (APOC3) | |
| EP2683826B1 (en) | Use of aptamers in therapy and/or diagnosis of autoimmune diseases | |
| US20200339984A1 (en) | Multivalent oligonucleotide assemblies | |
| EP1809738B1 (en) | Compositions and methods for treating hyperproliferative disorders | |
| US20220242963A1 (en) | B-cell activating cd73 antibodies | |
| WO2016115500A1 (en) | Cell penetrating antibodies | |
| CN109069604A (zh) | 新抗原组合物及其在免疫肿瘤治疗中的使用方法 | |
| CA3114302A1 (en) | Methods and compositions for selection of functional aptamers | |
| KR20180033606A (ko) | 베타-ENaC-관련 질환을 치료하기 위한 유기 조성물 | |
| US20250313837A1 (en) | Products and compositions | |
| US20230193286A1 (en) | Cytotoxic t-lymphocyte binding aptamers | |
| US12146140B2 (en) | T-lymphocyte binding aptamers | |
| EP2350131A2 (en) | Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling | |
| US20230193285A1 (en) | Bispecific personalized aptamers | |
| CN121532196A (zh) | 半乳糖凝集素-1作为免疫检查点在制备肿瘤免疫治疗药物中的应用以及该药物 | |
| JP2022513082A (ja) | 免疫応答を調節するためのIRE1α-XBP1シグナル伝達経路バイオマーカーの使用 | |
| CN117280033A (zh) | T-淋巴细胞结合适体 | |
| WO2020146801A1 (en) | Stem-loop compositions and methods for inhibiting vascular endothelial growth factor | |
| CN120456911A (zh) | 用于抑制补体组分C3(C3)表达的RNAi剂、其药物组合物及使用方法 | |
| KR101753457B1 (ko) | 암 줄기 유사세포 검출용 바이오마커 gpr50 및 이의 용도 | |
| Vandenbriele et al. | The role of PEAR1 in platelets and Endothelial cell Biology |